OBJECTIVE: To investigate the efficacy of duloxetine in the treatment of pain and improvement in functional impairment and quality of life in patients with fibromyalgia from a pooled analysis of 4placebo-controlled, double-blind, randomized trials. METHOD:Patients were eligible for inclusion in the studies if they were at least 18 years of age, met criteria for fibromyalgia as defined by the American College of Rheumatology, and had specified minimum pain severity scores. Across all studies, 797 patients receivedduloxetine 60-120 mg/d and 535 patients received placebo. Pain was assessed by the Brief Pain Inventory (BPI) 24-hour average pain severity score; other efficacy measures included the Clinical Global Impressions-Severity of Illness scale (CGI-S), Patient Global Impressions-Improvement scale (PGI-I), 17-item Hamilton Depression Rating Scale (HDRS-17), Fibromyalgia Impact Questionnaire (FIQ) total score, BPI pain interference items, Sheehan Disability Scale (SDS), and Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) mental and physical components. Changes from baseline to endpoint (last observation carried forward) for most of the above efficacy measures were analyzed using an analysis-of-covariance model. RESULTS: After 12 weeks of treatment, pain was significantly reduced in patients treated with duloxetine (P < .001) compared with placebo. In addition, duloxetine was superior to placebo in improving CGI-S (P < .001); PGI-I (P < .001); FIQ total (P < .001); HDRS-17 total (P = .003); SDS global functioning (P < .001), work/school (P = .018), and family life (P < .001); SF-36 mental (P < .001) and physical (P = .026) component; and BPI pain interference (P < .001) scores. Treatment-by-subgroup interactions were not significant for sex (P = .320), age (P = .362), or race (P = .180). CONCLUSIONS: This pooled analysis provides evidence that 12 weeks of treatment with duloxetine 60-120 mg/d effectively improves fibromyalgia symptoms and may offer benefits beyond pain relief.
RCT Entities:
OBJECTIVE: To investigate the efficacy of duloxetine in the treatment of pain and improvement in functional impairment and quality of life in patients with fibromyalgia from a pooled analysis of 4 placebo-controlled, double-blind, randomized trials. METHOD:Patients were eligible for inclusion in the studies if they were at least 18 years of age, met criteria for fibromyalgia as defined by the American College of Rheumatology, and had specified minimum pain severity scores. Across all studies, 797 patients received duloxetine 60-120 mg/d and 535 patients received placebo. Pain was assessed by the Brief Pain Inventory (BPI) 24-hour average pain severity score; other efficacy measures included the Clinical Global Impressions-Severity of Illness scale (CGI-S), Patient Global Impressions-Improvement scale (PGI-I), 17-item Hamilton Depression Rating Scale (HDRS-17), Fibromyalgia Impact Questionnaire (FIQ) total score, BPI pain interference items, Sheehan Disability Scale (SDS), and Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) mental and physical components. Changes from baseline to endpoint (last observation carried forward) for most of the above efficacy measures were analyzed using an analysis-of-covariance model. RESULTS: After 12 weeks of treatment, pain was significantly reduced in patients treated with duloxetine (P < .001) compared with placebo. In addition, duloxetine was superior to placebo in improving CGI-S (P < .001); PGI-I (P < .001); FIQ total (P < .001); HDRS-17 total (P = .003); SDS global functioning (P < .001), work/school (P = .018), and family life (P < .001); SF-36 mental (P < .001) and physical (P = .026) component; and BPI pain interference (P < .001) scores. Treatment-by-subgroup interactions were not significant for sex (P = .320), age (P = .362), or race (P = .180). CONCLUSIONS: This pooled analysis provides evidence that 12 weeks of treatment with duloxetine 60-120 mg/d effectively improves fibromyalgia symptoms and may offer benefits beyond pain relief.
Authors: Lesley M Arnold; Amy Rosen; Yili Lu Pritchett; Deborah N D'Souza; David J Goldstein; Smriti Iyengar; Joachim F Wernicke Journal: Pain Date: 2005-11-17 Impact factor: 6.961
Authors: Joel Raskin; Yili L Pritchett; Fujun Wang; Deborah N D'Souza; Amy L Waninger; Smriti Iyengar; Joachim F Wernicke Journal: Pain Med Date: 2005 Sep-Oct Impact factor: 3.750
Authors: Smriti Iyengar; Amy A Webster; Susan K Hemrick-Luecke; Jimmy Yu Xu; Rosa Maria A Simmons Journal: J Pharmacol Exp Ther Date: 2004-07-13 Impact factor: 4.030
Authors: D T Wong; F P Bymaster; D A Mayle; L R Reid; J H Krushinski; D W Robertson Journal: Neuropsychopharmacology Date: 1993-01 Impact factor: 7.853
Authors: Jon I Russell; Philip J Mease; Timothy R Smith; Daniel K Kajdasz; Madelaine M Wohlreich; Michael J Detke; Daniel J Walker; Amy S Chappell; Lesley M Arnold Journal: Pain Date: 2008-04-18 Impact factor: 6.961
Authors: Brian Noehren; Dana L Dailey; Barbara A Rakel; Carol G T Vance; Miriam B Zimmerman; Leslie J Crofford; Kathleen A Sluka Journal: Phys Ther Date: 2014-09-11
Authors: Eric W de Heer; Jack Dekker; Jonna F van Eck van der Sluijs; Aartjan Tf Beekman; Harm Wj van Marwijk; Tjalling J Holwerda; Pierre M Bet; Joost Roth; Leona Hakkaart-Van Roijen; Lianne Ringoir; Fiona Kat; Christina M van der Feltz-Cornelis Journal: BMC Psychiatry Date: 2013-05-24 Impact factor: 3.630